Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Castlebay Investments David F. Ridland | “Spirax Group is, almost literally, a descendant of the Boulton & Watt story: a global leader in steam, fluid and thermal energy management, serving industrial customers for whom these systems are mission-critical infrastructure. The group operates three linked divisions — Steam Thermal Solutions and Electric Thermal Solutions, which sell and service the industrial steam and electric heating systems that keep factories, hospitals and food plants running; and Watson-Marlow, which supplies precision pumps and single-use fluid-path technology into biopharmaceutical manufacturing. We purchased an initial 2% fund position in Spirax for reasons that map directly onto the questions we ask of every candidate: does it earn a return on capital that clears its cost of capital by a wide and defensible margin; do its revenues have a genuine multi-year runway rather than a single cycle of demand; and are we being offered the stock at an attractive valuation entry point? On the first of these points, Spirax's direct-sales, 'razor-and-blade' commercial model — proprietary equipment followed by decades of recurring consumables, spares and service revenue — produces a ROIC that sits comfortably clear of its cost of capital. The recurring nature of its service also helps in sustaining that spread through the cycle rather than requiring it to be re-earned on every piece of new equipment sold. Secondly, the group's revenue runway is unusually well diversified, with Steam Thermal Solutions and Electric Thermal Solutions offering a long growth profile with a highly durable tail of mission-critical replacement and service revenue. Watson-Marlow's business gives exposure to single-use fluid-path technology in biopharmaceutical manufacturing, giving the group a genuine structural growth trajectory on top, as biologic drug production continues to shift away from older stainless-steel systems. On the third, valuation point, we believe the rising earnings growth profile is attractive. Taken together, we see a mature, cash-generative core trading at a valuation that does not yet fully credit the structural growth engine sitting inside it. Put in the lifecycle language introduced earlier in this letter, Steam Thermal Solutions and Electric Thermal Solutions are unambiguously Stage 3, while Watson-Marlow still exhibits genuine Stage 2 characteristics. The market, in our judgement, persists in valuing the group primarily through the lens of its more cyclical industrial activity. If Edwards LifeSciences, the sale of which we reported in our last letter, was a Stage 3 business priced as Stage 2, Spirax is close to the mirror image—a Stage 2 growth engine housed inside a Stage 3 valuation.” | NEUTRAL | Q2 2026 Jul 11, 2026 | View Pitch |
Bronte Capital Amalthea Fund John Hempton | “The manager admits to making a valuation mistake by holding Spirax Group as its multiples rose to ten times revenue due to temporary pandemic-era supply chain dynamics. Despite this error, the company's core bioprocessing pump business remains highly competitive with high customer switching costs. With the share price having declined significantly, the manager remains confident in its long-term prospects.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
